Burchardi, Hilmar

[["dc.bibliographiccitation.firstpage","1220"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Intensive Care Medicine"],["dc.bibliographiccitation.lastpage","1223"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Neilson, A. R."],["dc.contributor.author","Moerer, Onnen"],["dc.contributor.author","Burchardi, Hilmar"],["dc.contributor.author","Schneider, H."],["dc.date.accessioned","2018-11-07T10:48:29Z"],["dc.date.available","2018-11-07T10:48:29Z"],["dc.date.issued","2004"],["dc.description.abstract","Objective. To evaluate LOS in developing a concept of borderline ICU LOS for a realistic reimbursement of intensive care. Design. Retrospective analysis of LOS and cost data extracted from patients' electronic records. Setting. Surgical ICU of the University Hospital Gottingen, Germany. Patients and participants. All adult ICU admissions with LOS >24 h over a 24-month period (1 January 2000 to 31 December 2001; n=1631.) Interventions. None. Measurements and results. Cluster analysis partitioned the ICU population into three homogenous groups based on ICU LOS and total direct costs: cluster 1 (n=1405; mean LOS=2.8; mean cost=e2399); cluster 2 (n=190; mean LOS=13.4; mean cost=e12,754); cluster 3 (n=36; mean LOS=34.9; mean cost=e34,173). Cost distribution between cluster 1 and clusters 2 and 3 combined was 48 vs 52%. Upper 95 percentile LOS of 6.7 allowed cluster 1 to be replaced by an LOS profile population of less than or equal to 7 days population (n=1355; 96% population and 91% total ICU cost overlap with cluster 1) representing 83% of total ICU population and 44% of total ICU costs. Stratification of >7 day population into LOS less than or >20 days (n=220; n=56) were further differentiated by mortality (11 vs 23%) and sepsis incidence (33 vs 79%). Conclusions. It may be feasible to formulate a LOS-based reimbursement scheme for ICU services in Germany based on the selection of (appropriate) patients' ICU LOS profiles."],["dc.identifier.doi","10.1007/s00134-004-2168-x"],["dc.identifier.isi","000221730300034"],["dc.identifier.pmid","14985961"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48204"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0342-4642"],["dc.title","A new concept for DRG-based reimbursement of services in German intensive care units: results of a pilot study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Intensive Care Medicine"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Neilson, A."],["dc.contributor.author","Moerer, Onnen"],["dc.contributor.author","Burchardi, Hilmar"],["dc.contributor.author","Schneider, H."],["dc.date.accessioned","2018-11-07T10:36:35Z"],["dc.date.available","2018-11-07T10:36:35Z"],["dc.date.issued","2003"],["dc.format.extent","S93"],["dc.identifier.isi","000185745400349"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/45359"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","New york"],["dc.relation.conference","16th Annual Congress of the European-Society-of-Internsive-Care-Medicine (ESICM)"],["dc.relation.eventlocation","AMSTERDAM, NETHERLANDS"],["dc.relation.issn","0342-4642"],["dc.title","DRG-based reimbursement of services in German intensive care units: A new concept"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Intensive Care Medicine"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Moerer, Onnen"],["dc.contributor.author","Neilson, A."],["dc.contributor.author","Burchardi, Hilmar"],["dc.contributor.author","Schneider, H."],["dc.date.accessioned","2018-11-07T10:36:34Z"],["dc.date.available","2018-11-07T10:36:34Z"],["dc.date.issued","2003"],["dc.format.extent","S94"],["dc.identifier.isi","000185745400356"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/45358"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","New york"],["dc.relation.conference","16th Annual Congress of the European-Society-of-Internsive-Care-Medicine (ESICM)"],["dc.relation.eventlocation","AMSTERDAM, NETHERLANDS"],["dc.relation.issn","0342-4642"],["dc.title","Relationship of treatment costs with severity scores in ICU patients"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Value in Health"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Neilson, A."],["dc.contributor.author","Schneider, H."],["dc.contributor.author","Burchardi, Hilmar"],["dc.contributor.author","Chinn, C."],["dc.contributor.author","Clouth, J."],["dc.contributor.author","Graebe, A."],["dc.date.accessioned","2018-11-07T09:54:53Z"],["dc.date.available","2018-11-07T09:54:53Z"],["dc.date.issued","2002"],["dc.format.extent","563"],["dc.identifier.doi","10.1016/S1098-3015(10)61483-0"],["dc.identifier.isi","000178998800292"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/36634"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Blackwell Publishing Inc"],["dc.publisher.place","Malden"],["dc.relation.issn","1098-3015"],["dc.title","Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis: A cross-national comparison of three European countries"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Intensive Care Medicine"],["dc.bibliographiccitation.volume","27"],["dc.contributor.author","Moerer, Onnen"],["dc.contributor.author","Hofmann, M."],["dc.contributor.author","Herklotz, A."],["dc.contributor.author","Schmid, A."],["dc.contributor.author","Schneider, H."],["dc.contributor.author","Burchardi, Hilmar"],["dc.date.accessioned","2018-11-07T08:42:20Z"],["dc.date.available","2018-11-07T08:42:20Z"],["dc.date.issued","2001"],["dc.format.extent","S283"],["dc.identifier.isi","000171249400577"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19672"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","New york"],["dc.relation.issn","0342-4642"],["dc.title","Direct costs of severe sepsis patients in three German intensive care units based on retrospective electronic patient record analysis of resource use"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Value in Health"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Neilson, A."],["dc.contributor.author","Moerer, Onnen"],["dc.contributor.author","Burchardi, Hilmar"],["dc.contributor.author","Schneider, H."],["dc.date.accessioned","2018-11-07T10:35:18Z"],["dc.date.available","2018-11-07T10:35:18Z"],["dc.date.issued","2003"],["dc.format.extent","711"],["dc.identifier.isi","000186300900261"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/45063"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Blackwell Publishing Inc"],["dc.publisher.place","Malden"],["dc.relation.issn","1098-3015"],["dc.title","Research 5539: Comparison of actual costs and DRG-based reimbursement of intensive care in German ICUs"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","217"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Journal of Critical Care"],["dc.bibliographiccitation.lastpage","227"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Neilson, A. R."],["dc.contributor.author","Burchardi, Hilmar"],["dc.contributor.author","Chinn, C."],["dc.contributor.author","Clouth, J."],["dc.contributor.author","Schneider, H."],["dc.contributor.author","Angus, D."],["dc.date.accessioned","2018-11-07T10:34:25Z"],["dc.date.available","2018-11-07T10:34:25Z"],["dc.date.issued","2003"],["dc.description.abstract","Drotrecogin alfa (activated) (Xigris; Eli Lilly and Company, Indianapolis, IN) significantly reduced mortality in severe sepsis in the PROWESS trial. We evaluate the cost-effectiveness of drotrecogin alfa (activated) as an adjunct to standard therapy from the German healthcare payer's perspective with respect to patients with 1) severe sepsis and 2) severe sepsis and multiple organ failure the approved European indication. Hospital resource use based on PROWESS was valued using German unit costs. German life-tables and long-term survival assumptions determined life-years gained. European and German healthcare resource use data are examined in the sensitivity analysis. We assumed a unit price of Euro237.50 for drotrecogin alfa (activated). Per patient treated, drotrecogin alfa (activated) increased costs by Euro7,500, and hospital costs by Euro900 for all patients (Euro7,400 and Euro1,500 respectively for the approved indication) and survival by 0.59 life years (0.87 life years respectively for the approved indication). Thus drotrecogin alfa (activated) cost Euro14,100 (Euro17,700 discounting life years at 3%) per life year gained for all patients (Euro10,200 and Euro12,900, respectively, for the approved indication). Testing the unit cost of drotrecogin alfa (activated), pattern of resource use, and survival benefit, demonstrated that cost-effectiveness lies well within the range of other life saving interventions in Germany representing good economic value. (C) 2003 Elsevier Inc. All rights reserved."],["dc.identifier.doi","10.1016/j.jcrc.2003.10.005"],["dc.identifier.isi","000187717500004"],["dc.identifier.pmid","14691895"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/44867"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0883-9441"],["dc.title","Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","793"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","PharmacoEconomics"],["dc.bibliographiccitation.lastpage","813"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Burchardi, Hilmar"],["dc.contributor.author","Schneider, H."],["dc.date.accessioned","2018-11-07T10:53:02Z"],["dc.date.available","2018-11-07T10:53:02Z"],["dc.date.issued","2004"],["dc.description.abstract","Severe sepsis remains both an important clinical challenge and an economic burden in intensive care. An estimated 750000 cases occur each year in the US alone (300 cases per 100000 population). Lower numbers are estimated for most European countries (e.g. Germany and Austria: 54-116 cases per year per 100000). Sepsis patients are generally treated in intensive care units (ICUs) where close supervision and intensive care treatment by a competent team with adequate equipment can be provided. Staffing costs represent from 40% to >60% of the total ICU budget. Because of the high proportion of fixed costs in ICU treatment, the total cost of ICU care is mainly dependent on the length of ICU stay (ICU-LOS). The average total cost per ICU day is estimated at approximately C1200 for countries with a highly developed healthcare system (based on various studies conducted between 1989 and 2001 and converted at 2003 currency rates). Patients with infections and severe sepsis require a prolonged ICU-LOS, resulting in higher costs of treatment compared with other ICU patients. US cost-of-illness studies focusing on direct costs per sepsis patient have yielded estimates of C34000, whereas European studies have given lower cost estimates, ranging from 623 000 to C29000. Direct costs, however, make up only about 20-30% of the cost of illness of severe sepsis. Indirect costs associated with severe sepsis account for 70-80% of costs and arise mainly from productivity losses due to mortality. Because of increasing healthcare cost pressures worldwide, economic issues have become important for the introduction of new innovations. This is evident when introducing new biotechnology products, such as drotrecogin-alpha (activated protein Q, into specific therapy for severe sepsis. Data so far suggest that when drotrecogin-a treatment is targeted to those patients most likely to achieve the greatest benefit, the drug is cost effective by the standards of other well accepted life-saving interventions."],["dc.identifier.doi","10.2165/00019053-200422120-00003"],["dc.identifier.isi","000223645900003"],["dc.identifier.pmid","15294012"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/49258"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Adis International Ltd"],["dc.relation.issn","1170-7690"],["dc.title","Economic aspects of severe sepsis - A review of intensive care unit costs, cost of illness and cost effectiveness of therapy"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","239"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Critical Care"],["dc.bibliographiccitation.lastpage","249"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Neilson, A. R."],["dc.contributor.author","Burchardi, Hilmar"],["dc.contributor.author","Schneider, H."],["dc.date.accessioned","2018-11-07T10:56:15Z"],["dc.date.available","2018-11-07T10:56:15Z"],["dc.date.issued","2005"],["dc.description.abstract","Purpose: To measure the cost-effectiveness of a specific polyclonal intravenous immune globulin preparation (Pentaglobin) in adult patients treated for severe sepsis and septic shock. Materials and Methods: Effectiveness data from a meta-analysis of 9 randomized trials (N = 435) were used to populate a decision model to estimate the cost-effectiveness of Pentaglobin and its comparator standard therapy from the hospital perspective in Germany. Primary outcome: all-cause morality; secondary outcome: intensive care unit (ICU) length of stay. Benefit was expressed as lives saved (LS). Published cost data were applied to assess differences in ICU treatment costs. Cost-effectiveness was calculated as incremental cost per LS. Results: Pentaglobin reduced the risk of mortality (P <.001) but had no effect on ICU length of stay. A baseline risk of mortality of 0.4434 (risk ratio = 0.5652; absolute risk reduction = 0.1928; number-needed-to-treat = 5.19) increased ICU treatment costs with Pentaglobin by euro2037 (euro22711 vs euro24747) with a cost per LS of euro10565. Sensitivity analyses on baseline mortality risk (95% confidence interval 0.3293-0.5162) and risk ratio (95% confidence interval 0.4306-0.7420) yielded a cost per LS range of euro5715 to euro28443 with a 56.3% probability of cost-effectiveness of euro12 000 or less. Conclusions: Pentaglobin is a promising adjuvant therapy both clinically and economically for treatment of adults with severe sepsis and septic shock. (c) 2005 Elsevier Inc. All rights reserved."],["dc.identifier.doi","10.1016/j.jcrc.2005.03.003"],["dc.identifier.isi","000233277600007"],["dc.identifier.pmid","16253792"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/49970"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","W B Saunders Co"],["dc.relation.issn","0883-9441"],["dc.title","Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Intensive Care Medicine"],["dc.bibliographiccitation.volume","28"],["dc.contributor.author","Neilson, A. R."],["dc.contributor.author","Schneider, H."],["dc.contributor.author","Chinn, C."],["dc.contributor.author","Clouth, J."],["dc.contributor.author","Burchardi, Hilmar"],["dc.date.accessioned","2018-11-07T10:05:28Z"],["dc.date.available","2018-11-07T10:05:28Z"],["dc.date.issued","2002"],["dc.format.extent","S161"],["dc.identifier.isi","000178345900621"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38897"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","New york"],["dc.relation.conference","15th Annual Congress on European-Society-of-Internsive-Care-Medicine"],["dc.relation.eventlocation","BARCELONA, SPAIN"],["dc.relation.issn","0342-4642"],["dc.title","Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]